STERIS plc (NYSE:STE) Shares Acquired by Central Valley Advisors LLC

Central Valley Advisors LLC grew its holdings in shares of STERIS plc (NYSE:STE) by 10.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,182 shares of the medical equipment provider’s stock after purchasing an additional 609 shares during the period. Central Valley Advisors LLC’s holdings in STERIS were worth $1,271,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Bleakley Financial Group LLC raised its stake in STERIS by 8.7% in the third quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock valued at $407,000 after buying an additional 134 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after acquiring an additional 529,308 shares in the last quarter. Assetmark Inc. raised its position in shares of STERIS by 24.6% in the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after purchasing an additional 2,647 shares during the last quarter. KBC Group NV raised its position in shares of STERIS by 52.0% in the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock valued at $2,928,000 after purchasing an additional 4,132 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in STERIS in the 3rd quarter worth approximately $9,949,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.14% of the company’s stock.

STERIS Price Performance

NYSE:STE opened at $209.96 on Friday. The firm’s fifty day moving average is $212.23 and its two-hundred day moving average is $224.79. The firm has a market cap of $20.72 billion, a price-to-earnings ratio of 47.94 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS plc has a one year low of $197.82 and a one year high of $248.24.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.03 EPS. Research analysts expect that STERIS plc will post 9.1 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.09%. The ex-dividend date of this dividend was Tuesday, November 19th. STERIS’s dividend payout ratio is currently 52.05%.

Analyst Ratings Changes

A number of brokerages have issued reports on STE. Stephens restated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research note on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Monday, November 18th. Finally, Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.